Pfizer, BioNTech shares gain as more data backs vaccine candidate By Reuters

Pfizer, BioNTech shares gain as more data backs vaccine candidate


2/2
© Reuters. FILE PHOTO: A man walks past a sign outside Pfizer Headquarters in the Manhattan borough of New York City

2/2

(Reuters) – Shares of Pfizer Inc (NYSE:) and U.S.-listed shares of partner BioNTech SE (NASDAQ:) rose on Friday after they released additional data for their experimental coronavirus vaccine and reiterated they were on track to seek a regulatory review in October.

Pfizer has said repeatedly since June that it was targeting October for its application and the companies started a large late-stage study last month of the candidate vaccine, one of the few globally in later stages of development.

On Thursday they reported data from previous early-stage trials of the vaccine, BNT162b2, that showed it induced similar immune responses and had milder side effects than prior data on another candidate.

Pfizer stock, down 1% this year, has trailed the stellar rises in value of major pharmaceutical companies this year. Moderna (NASDAQ:) and Britain’s AstraZeneca (NYSE:) are among those to have moved into late-stage trials.

Raymond James European Strategist Chris Bailey said the Pfizer/BioNTech release had contributed to a more optimistic mood on stock markets on Friday.

Pfizer shares rose 1% while those of BioNTech were 6% higher before the bell.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *


About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.


CONTACT US

CALL US ANYTIME